Jillian Oakleaf
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AstraZeneca at 35.8% of the total. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $60.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Karyopharm Therapeutics Inc.$4K
- Johnson & Johnson$1K
- Dendreon Pharmaceuticals LLC$692
- Astellas Pharma US Inc$580
- Pfizer$480
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$8,13053%
- Food & beverage$6,53042%
- Education$7635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 25 | $5,517 |
| Karyopharm Therapeutics Inc. | 8 | $3,656 |
| Johnson & Johnson | 39 | $1,343 |
| Dendreon Pharmaceuticals LLC | 16 | $692 |
| Astellas Pharma US Inc | 10 | $580 |
| Pfizer | 21 | $480 |
| Sumitomo Pharma America, Inc. | 22 | $442 |
| Novartis | 11 | $279 |
| Merck | 12 | $278 |
| Gilead | 8 | $271 |
| Bayer | 9 | $231 |
| Urogen Pharma, Inc. | 7 | $147 |
| Accord Healthcare, Inc. | 7 | $118 |
| Daiichi Sankyo Inc. | 5 | $112 |
| Vertex | 4 | $109 |
| Epizyme, Inc. | 1 | $103 |
| Olympus America Inc. | 4 | $95 |
| Tolmar, Inc. | 4 | $92 |
| Telix Pharmaceuticals | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $89 |
| Sanofi | 4 | $79 |
| Immunitybio, Inc. | 2 | $76 |
| AbbVie | 3 | $55 |
| Endo USA, Inc. | 3 | $55 |
| Myriad Genetic Laboratories, Inc. | 2 | $53 |
| Amgen | 2 | $49 |
| Antares Pharma, Inc. | 3 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $43 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Seagen Inc. | 2 | $41 |
| Coloplast | 2 | $33 |
| Verity Pharmaceuticals Inc. | 2 | $31 |
| Pharmaessentia USA Corporation | 1 | $23 |
| Genentech USA, Inc. | 2 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,423 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nystatin | 12 | $120 |
| Potassium Chloride | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Other family in Tulsa
- Candy WilliamsTulsa$22K
- Lee MatlockTulsa$15K
- Vanessa ZickefooseTulsa$13K
- Erin RowanTulsa$13K
- Lora HortonTulsa$12K
- Darla NorrisTulsa$11K
- Cristina BarnesTulsa$11K
- Ashley RiouseTulsa$10K
- Jaclyn DrassTulsa$9K
- Teresa DonnellTulsa$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.